Adding a new once-daily pill to a combination of drugs already used on the NHS could help patients with a with an incurable blood cancer live longer without the disease getting worse, according to researchers.
A trial found that patients on the triplet therapy – which included the new treatment mezigdomide – lived more than twice as long without their cancer progressing.
